Balyasny Asset Management
FSTX

Balyasny Asset Management’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Balyasny Asset Management’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-502,800
Closed -$3.18M – 3370
2022
Q4 		$3.18M Buy
+502,800
New +$2.78M 0.01% 1211

Balyasny Asset Management's FSTX Position: Q4 2022 in Review

Balyasny Asset Management sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q4 2022, closing a stake of 14,483 shares — an estimated $80.2K sold.

Balyasny Asset Management first reported a position in FSTX in Q3 2022 and held it in 1 quarter. The position peaked at $74K in Q3 2022. 59 funds tracked by Wall St. Rank hold FSTX as of Q4 2022.

  • Balyasny Asset Management reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Balyasny Asset Management sold 14,483 F-star Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $80.2K.
  • Balyasny Asset Management first reported a position in F-star Therapeutics, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Balyasny Asset Management's F-star Therapeutics, Inc. Common Stock position peaked at $74K in Q3 2022.
  • 59 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.